Cerbios' Senior Scientist on Antibody Drug Conjugates

Friday, April 6, 2018 @ 12:00 am

During the DCAT week, an interview on ADCs with Vítor Sousa, Senior Manager, R&D Biological Division, Cerbios-Pharma SA, has been published on PHARMA HORIZON.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Mabylon: Peanut allergy treatment in Phase I clinical trial

First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions MY006' tri-specific format allows for simultaneous recognition of epitopes across multiple allergens. It has been designed for sustained serum levels, high stability and continuous protection wit
December 18, 2025

Topadur: Matthias Schäfer becomes Chief Executive Officer

Founder and President of the Board Dr. Reto Naef assumes the role of Senior Scientific Advisor, continuing to support the company’s scientific direction Company enters next phase of clinical advancement with programs progressing toward strategic milestones
December 17, 2025

Allegria Therapeutics secures USD 5.1 million seed extension financing

Allegria Therapeutics (ALLEGRIA), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today the successful completion of a USD 5.1 million seed extension financing.
December 11, 2025

ten23 health supports commercial product testing for US customers following FDA approvals

ten23 health, the human-centric and sustainable CDMO partner of choice for the pharmaceutical and biotechnology industries, today announced that its recently established and Swissmedic approved Quality Control (QC) laboratories in both Basel and Visp, Switzerland, have been formally approved by the U.S. Food and Drug Administration (FDA). The approval was granted in connection with registering ten
December 9, 2025

Cosmo flash update: Strong Breezula phase 3 results

December 5, 2025